Innova Captab Limited has informed the Exchange regarding 'Announcement under Regulation 30 SEBI (LODR)2015 - Recommendation of GMP Compliance Certificate by the State Service of Ukraine on Medicines and Drugs Control'.
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Innova Captab has disclosed under SEBI LODR Regulation 30 that the State Service of Ukraine on Medicines and Drugs Control has recommended a Good Manufacturing Practice (GMP) Compliance Certificate for the company. GMP certification is a key regulatory requirement that allows pharmaceutical manufacturers to supply products in regulated international markets. This recommendation from the Ukrainian regulator signals that the company's manufacturing facilities meet international quality standards. It paves the way for exports of pharmaceutical formulations to Ukraine and potentially other CIS markets that recognise this certification. The announcement reflects the company's ongoing efforts to expand its international footprint.
Positive development for shareholders — GMP clearance from a foreign regulator strengthens Innova Captab's export credentials and opens a new revenue stream from Ukraine and CIS markets. Could support future order inflows, though actual business impact will depend on product registrations and supply orders that follow.